{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:36Z","timestamp":1792047816627,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T031921\/1"],"award-info":[{"award-number":["MR\/T031921\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/ P003214\/1"],"award-info":[{"award-number":["MR\/ P003214\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010450","name":"Ministry of Higher Education and Scientific Research","doi-asserted-by":"publisher","award":["368477"],"award-info":[{"award-number":["368477"]}],"id":[{"id":"10.13039\/100010450","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academy of Medical Sciences Starter Grants for Clinical Lecturers","award":["SGL021\\1092"],"award-info":[{"award-number":["SGL021\\1092"]}]},{"name":"Kidney Research UK Innovation Grant","award":["IN_004_20190305"],"award-info":[{"award-number":["IN_004_20190305"]}]},{"name":"Kidney Research UK Intercalation Degree Award","award":["ID_008_20170331"],"award-info":[{"award-number":["ID_008_20170331"]}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","award":["RP_031_20180306"],"award-info":[{"award-number":["RP_031_20180306"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/16\/35\/32139"],"award-info":[{"award-number":["PG\/16\/35\/32139"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR055670"],"award-info":[{"award-number":["R01AR055670"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellington Research Fund","award":["No.217883"],"award-info":[{"award-number":["No.217883"]}]},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["18\/0005795"],"award-info":[{"award-number":["18\/0005795"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes mellitus is a chronic disease which is detrimental to cardiovascular health, often leading to secondary microvascular complications, with huge global health implications. Therapeutic interventions that can be applied to multiple vascular beds are urgently needed. Diabetic retinopathy (DR) and diabetic kidney disease (DKD) are characterised by early microvascular permeability changes which, if left untreated, lead to visual impairment and renal failure, respectively. The heparan sulphate cleaving enzyme, heparanase, has previously been shown to contribute to diabetic microvascular complications, but the common underlying mechanism which results in microvascular dysfunction in conditions such as DR and DKD has not been determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, two mouse models of heparan sulphate depletion (enzymatic removal and genetic ablation by endothelial specific Exotosin-1 knock down) were utilized to investigate the impact of endothelial cell surface (i.e., endothelial glycocalyx) heparan sulphate loss on microvascular barrier function. Endothelial glycocalyx changes were measured using fluorescence microscopy or transmission electron microscopy. To measure the impact on barrier function, we used sodium fluorescein angiography in the eye and a glomerular albumin permeability assay in the kidney. A type 2 diabetic (T2D,\n                      <jats:italic>db\/db<\/jats:italic>\n                      ) mouse model was used to determine the therapeutic potential of preventing heparan sulphate damage using treatment with a novel heparanase inhibitor, OVZ\/HS-1638. Endothelial glycocalyx changes were measured as above, and microvascular barrier function assessed by albumin extravasation in the eye and a glomerular permeability assay in the kidney.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both models of heparan sulphate depletion, endothelial glycocalyx depth was reduced and retinal solute flux and glomerular albumin permeability was increased. T2D mice treated with OVZ\/HS-1638 had improved endothelial glycocalyx measurements compared to vehicle treated T2D mice and were simultaneously protected from microvascular permeability changes associated with DR and DKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We demonstrate that endothelial glycocalyx heparan sulphate plays a common mechanistic role in microvascular barrier function in the eye and kidney. Protecting the endothelial glycocalyx damage in diabetes, using the novel heparanase inhibitor OVZ\/HS-1638, effectively prevents microvascular permeability changes associated with DR and DKD, demonstrating a novel systemic approach to address diabetic microvascular complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02133-1","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:02:33Z","timestamp":1706781753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Heparanase inhibition as a systemic approach to protect the\u00a0endothelial glycocalyx and prevent microvascular complications in diabetes"],"prefix":"10.1186","volume":"23","author":[{"given":"Monica","family":"Gamez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham E.","family":"Elhegni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Ho","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neill W.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Onions","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Wasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina D.","family":"Ramnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenton P.","family":"Arkill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy E.","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Zubkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin I.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denize","family":"Atan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Satchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"1","key":"2133_CR1","first-page":"49","volume":"5","author":"O Gheith","year":"2015","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015;5(1):49\u201356.","journal-title":"J Nephropharmacol"},{"key":"2133_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.027","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology.\u00a02021 Nov;128(11):1580-1591. doi: 10.1016\/j.ophtha.2021.04.027","journal-title":"Ophthalmology"},{"issue":"1","key":"2133_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.dsx.2016.06.017","volume":"11","author":"S Verma","year":"2017","unstructured":"Verma S, Hussain ME. Obesity and diabetes: an update. Diabetes Metab Syndr. 2017;11(1):73\u20139.","journal-title":"Diabetes Metab Syndr"},{"issue":"14","key":"2133_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93751","volume":"2","author":"EJ Duh","year":"2017","unstructured":"Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14): e93751.","journal-title":"JCI Insight."},{"key":"2133_CR5","doi-asserted-by":"publisher","first-page":"1839809","DOI":"10.1155\/2017\/1839809","volume":"2017","author":"R Xue","year":"2017","unstructured":"Xue R, Gui D, Zheng L, Zhai R, Wang F, Wang N. Mechanistic insight and management of diabetic nephropathy: recent progress and future perspective. J Diabetes Res. 2017;2017:1839809.","journal-title":"J Diabetes Res"},{"issue":"13","key":"2133_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/archinte.1997.00440340025002","volume":"157","author":"SF Dinneen","year":"1997","unstructured":"Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157(13):1413\u20138.","journal-title":"Arch Intern Med"},{"issue":"8","key":"2133_CR7","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.2337\/diacare.26.8.2389","volume":"26","author":"KV Allen","year":"2003","unstructured":"Allen KV, Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care. 2003;26(8):2389\u201391.","journal-title":"Diabetes Care"},{"issue":"2","key":"2133_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2337\/diabetes.54.2.527","volume":"54","author":"R Klein","year":"2005","unstructured":"Klein R, Zinman B, Gardiner R, Suissa S, Donnelly SM, Sinaiko AR, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the renin-angiotensin system study. Diabetes. 2005;54(2):527\u201333.","journal-title":"Diabetes"},{"issue":"1","key":"2133_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10792-014-0018-6","volume":"35","author":"P Kotlarsky","year":"2015","unstructured":"Kotlarsky P, Bolotin A, Dorfman K, Knyazer B, Lifshitz T, Levy J. Link between retinopathy and nephropathy caused by complications of diabetes mellitus type 2. Int Ophthalmol. 2015;35(1):59\u201366.","journal-title":"Int Ophthalmol"},{"issue":"10","key":"2133_CR10","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.1167\/iovs.14-15001","volume":"55","author":"WJ Lee","year":"2014","unstructured":"Lee WJ, Sobrin L, Lee MJ, Kang MH, Seong M, Cho H. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3). Invest Ophthalmol Vis Sci. 2014;55(10):6547\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2133_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000726","volume":"7","author":"M Yamanouchi","year":"2019","unstructured":"Yamanouchi M, Mori M, Hoshino J, Kinowaki K, Fujii T, Ohashi K, et al. Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease. BMJ Open Diabetes Res Care. 2019;7(1): e000726.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9131","key":"2133_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"Group UPDS (UKPDS)","year":"1998","unstructured":"Group UPDS (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"key":"2133_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","volume":"51","author":"AW Stitt","year":"2016","unstructured":"Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156\u201386.","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"2133_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11892-021-01403-6","volume":"21","author":"LA Everett","year":"2021","unstructured":"Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2021;21(9):35.","journal-title":"Curr Diab Rep"},{"issue":"suppl_1","key":"2133_CR15","doi-asserted-by":"publisher","first-page":"s84","DOI":"10.2337\/diacare.27.2007.S84","volume":"27","author":"DS Fong","year":"2004","unstructured":"Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(suppl_1):s84\u20137.","journal-title":"Diabetes Care"},{"issue":"S1","key":"2133_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14007","volume":"22","author":"NM Selby","year":"2020","unstructured":"Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(S1):3\u201315.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2133_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.3964","volume":"226","author":"AH Salmon","year":"2012","unstructured":"Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol. 2012;226(4):562\u201374.","journal-title":"J Pathol"},{"issue":"3","key":"2133_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","volume":"454","author":"S Reitsma","year":"2007","unstructured":"Reitsma S, Slaaf DW, Vink H, Van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345\u201359.","journal-title":"Pflugers Arch"},{"issue":"6","key":"2133_CR19","doi-asserted-by":"publisher","first-page":"H811","DOI":"10.1152\/ajpheart.00764.2012","volume":"305","author":"Y Zeng","year":"2013","unstructured":"Zeng Y, Waters M, Andrews A, Honarmandi P, Ebong EE, Rizzo V, et al. Fluid shear stress induces the clustering of heparan sulfate via mobility of glypican-1 in lipid rafts. Am J Physiol Heart Circ Physiol. 2013;305(6):H811\u201320.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"2133_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/01.ATV.0000085630.24353.3D","volume":"23","author":"AA Constantinescu","year":"2003","unstructured":"Constantinescu AA, Vink H, Spaan JAE. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol. 2003;23(9):1541\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2133_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2337\/diabetes.55.02.06.db05-1103","volume":"55","author":"M Nieuwdorp","year":"2006","unstructured":"Nieuwdorp M, van Haeften TW, Gouverneur MCLG, Mooij HL, van Lieshout MHP, Levi M, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006;55(2):480\u20136.","journal-title":"Diabetes"},{"key":"2133_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.730621","author":"J Qu","year":"2021","unstructured":"Qu J, Cheng Y, Wu W, Yuan L, Liu X. Glycocalyx impairment in vascular disease: focus on inflammation. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.730621.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2133_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1172\/JCI13737","volume":"108","author":"G Duncan","year":"2001","unstructured":"Duncan G, McCormick C, Tufaro F. The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins. J Clin Invest. 2001;108(4):511\u20136.","journal-title":"J Clin Invest"},{"issue":"19","key":"2133_CR24","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1111\/j.1742-4658.2010.07798.x","volume":"277","author":"T Manon-Jensen","year":"2010","unstructured":"Manon-Jensen T, Itoh Y, Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 2010;277(19):3876\u201389.","journal-title":"FEBS J"},{"issue":"5","key":"2133_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.kint.2019.09.035","volume":"97","author":"RD Ramnath","year":"2020","unstructured":"Ramnath RD, Butler MJ, Newman G, Desideri S, Russell A, Lay AC, et al. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease. Kidney Int. 2020;97(5):951\u201365.","journal-title":"Kidney Int"},{"issue":"12","key":"2133_CR26","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/sj.ki.5001985","volume":"70","author":"MJ van den Hoven","year":"2006","unstructured":"van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006;70(12):2100\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"2133_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/0886022X.2017.1384391","volume":"39","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Liu J, Ten S, Zhang J, Yuan Y, Yu J, et al. Plasma heparanase is associated with blood glucose levels but not urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage. Ren Fail. 2017;39(1):698\u2013701.","journal-title":"Ren Fail"},{"issue":"13","key":"2133_CR28","doi-asserted-by":"publisher","first-page":"8239","DOI":"10.1167\/iovs.15-18025","volume":"56","author":"AMA El-Asrar","year":"2015","unstructured":"El-Asrar AMA, Alam K, Nawaz MI, Mohammad G, den Eynde KV, Siddiquei MM, et al. Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes. Invest Ophthalmol Vis Sci. 2015;56(13):8239\u201347.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"2133_CR29","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1021\/acschembio.8b00909","volume":"13","author":"OV Zubkova","year":"2018","unstructured":"Zubkova OV, Ahmed YA, Guimond SE, Noble SL, Miller JH, Alfred Smith RA, et al. Dendrimer heparan sulfate glycomimetics: potent heparanase inhibitors for anticancer therapy. ACS Chem Biol. 2018;13(12):3236\u201342.","journal-title":"ACS Chem Biol"},{"issue":"5647","key":"2133_CR30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1126\/science.1090497","volume":"302","author":"M Inatani","year":"2003","unstructured":"Inatani M, Irie F, Plump AS, Tessier-Lavigne M, Yamaguchi Y. Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science. 2003;302(5647):1044\u20136.","journal-title":"Science"},{"issue":"8","key":"2133_CR31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2014040350","volume":"26","author":"S Oltean","year":"2015","unstructured":"Oltean S, Qiu Y, Ferguson JK, Stevens M, Neal C, Russell A, et al. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J Am Soc Nephrol. 2015;26(8):1889\u2013904.","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"2133_CR32","first-page":"3788","volume":"56","author":"H Kobayashi","year":"1996","unstructured":"Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N, Webber KO, et al. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res. 1996;56(16):3788\u201395.","journal-title":"Cancer Res"},{"issue":"11","key":"2133_CR33","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1523\/JNEUROSCI.20-11-04099.2000","volume":"20","author":"GJ Jenniskens","year":"2000","unstructured":"Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J Neurosci. 2000;20(11):4099\u2013111.","journal-title":"J Neurosci"},{"issue":"13","key":"2133_CR34","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1074\/jbc.M104852200","volume":"277","author":"MABA Dennissen","year":"2002","unstructured":"Dennissen MABA, Jenniskens GJ, Pieffers M, Versteeg EMM, Petitou M, Veerkamp JH, et al. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies*. J Biol Chem. 2002;277(13):10982\u20136.","journal-title":"J Biol Chem"},{"issue":"51","key":"2133_CR35","doi-asserted-by":"publisher","first-page":"35621","DOI":"10.1074\/jbc.M109.009712","volume":"284","author":"SM Thompson","year":"2009","unstructured":"Thompson SM, Fernig DG, Jesudason EC, Losty PD, van de Westerlo EMA, van Kuppevelt TH, et al. Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics. J Biol Chem. 2009;284(51):35621\u201331.","journal-title":"J Biol Chem"},{"issue":"5","key":"2133_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154164","volume":"8","author":"M Crompton","year":"2023","unstructured":"Crompton M, Ferguson JK, Ramnath RD, Onions KL, Ogier AS, Gamez M, et al. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight. 2023;8(5): e154164.","journal-title":"JCI Insight"},{"issue":"1","key":"2133_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.kint.2018.08.024","volume":"95","author":"MJ Butler","year":"2019","unstructured":"Butler MJ, Ramnath R, Kadoya H, Desposito D, Riquier-Brison A, Ferguson JK, et al. Aldosterone induces albuminuria via matrix metalloproteinase\u2013dependent damage of the endothelial glycocalyx. Kidney Int. 2019;95(1):94\u2013107.","journal-title":"Kidney Int"},{"issue":"6","key":"2133_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12623","volume":"27","author":"CL Allen","year":"2020","unstructured":"Allen CL, Malhi NK, Whatmore JL, Bates DO, Arkill KP. Non-invasive measurement of retinal permeability in a diabetic rat model. Microcirculation. 2020;27(6): e12623.","journal-title":"Microcirculation"},{"issue":"5","key":"2133_CR39","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.kint.2017.12.003","volume":"93","author":"S Desideri","year":"2018","unstructured":"Desideri S, Onions KL, Qiu Y, Ramnath RD, Butler MJ, Neal CR, et al. A novel assay provides sensitive measurement of physiologically relevant changes in albumin permeability in isolated human and rodent glomeruli. Kidney Int. 2018;93(5):1086\u201397.","journal-title":"Kidney Int"},{"issue":"8","key":"2133_CR40","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1161\/ATVBAHA.111.225268","volume":"31","author":"EE Ebong","year":"2011","unstructured":"Ebong EE, Macaluso FP, Spray DC, Tarbell JM. Imaging the endothelial glycocalyx in vitro by rapid freezing\/freeze substitution transmission electron microscopy. Arterioscler Thromb Vasc Biol. 2011;31(8):1908\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2133_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/sj.ki.5002706","volume":"73","author":"MJ van den Hoven","year":"2008","unstructured":"van den Hoven MJ, Wijnhoven TJ, Li JP, Zcharia E, Dijkman HB, Wismans RG, et al. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int. 2008;73(3):278\u201387.","journal-title":"Kidney Int"},{"issue":"1","key":"2133_CR42","doi-asserted-by":"publisher","first-page":"F430","DOI":"10.1152\/ajprenal.00010.2006","volume":"292","author":"MJ Lazzara","year":"2007","unstructured":"Lazzara MJ, Deen WM. Model of albumin reabsorption in the proximal tubule. Am J Physiol Ren Physiol. 2007;292(1):F430\u20139.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"2133_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00438-022-01854-w","volume":"297","author":"R Khalil","year":"2022","unstructured":"Khalil R, Boels MGS, Bezuijen A, Boers JE, de Bruin PC, van Dijk MAAM, et al. Mutations in the heparan sulfate backbone elongating enzymes EXT1 and EXT2 have no major effect on endothelial glycocalyx and the glomerular filtration barrier. Mol Genet Genomics. 2022;297(2):397\u2013405.","journal-title":"Mol Genet Genomics"},{"issue":"737","key":"2133_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/pgmj.63.737.179","volume":"63","author":"MH Winterborn","year":"1987","unstructured":"Winterborn MH, Bradwell AR, Chesner IM, Jones GT. The origin of proteinuria at high altitude. Postgrad Med J. 1987;63(737):179\u201381.","journal-title":"Postgrad Med J"},{"issue":"3","key":"2133_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/ki.1979.141","volume":"16","author":"CE Mogensen","year":"1979","unstructured":"Mogensen CE, Vittinghus E, S\u00f8lling K. Abnormal albumin excretion after two provocative renal tests in diabetes: physical exercise and lysine injection. Kidney Int. 1979;16(3):385\u201393.","journal-title":"Kidney Int"},{"issue":"12","key":"2133_CR46","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.2337\/db14-0001","volume":"63","author":"R Goldberg","year":"2014","unstructured":"Goldberg R, Rubinstein AM, Gil N, Hermano E, Li JP, van der Vlag J, et al. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes. 2014;63(12):4302\u201313.","journal-title":"Diabetes"},{"issue":"2","key":"2133_CR47","first-page":"231","volume":"134","author":"SA Vinores","year":"1989","unstructured":"Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol. 1989;134(2):231\u20135.","journal-title":"Am J Pathol"},{"issue":"6","key":"2133_CR48","first-page":"742","volume":"62","author":"SA Vinores","year":"1990","unstructured":"Vinores SA, Campochiaro PA, Lee A, McGehee R, Gadegbeku C, Green WR. Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest. 1990;62(6):742\u201350.","journal-title":"Lab Invest"},{"issue":"5","key":"2133_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF00175927","volume":"230","author":"T Murata","year":"1992","unstructured":"Murata T, Ishibashi T, Inomata H. Immunohistochemical detection of extravasated fibrinogen (fibrin) in human diabetic retina. Graefes Arch Clin Exp Ophthalmol. 1992;230(5):428\u201331.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2133_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jcp.2005.035592","volume":"60","author":"KO Alsaad","year":"2007","unstructured":"Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007;60(1):18\u201326.","journal-title":"J Clin Pathol"},{"issue":"7","key":"2133_CR51","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.2337\/diacare.26.7.2150","volume":"26","author":"G Bruno","year":"2003","unstructured":"Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2003;26(7):2150\u20135.","journal-title":"Diabetes Care"},{"issue":"9","key":"2133_CR52","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1167\/iovs.11-7909","volume":"52","author":"SJ Clark","year":"2011","unstructured":"Clark SJ, Keenan TDL, Fielder HL, Collinson LJ, Holley RJ, Merry CLR, et al. Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. Invest Ophthalmol Vis Sci. 2011;52(9):6511\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"2133_CR53","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1182\/blood-2005-01-0254","volume":"106","author":"H Niemel\u00e4","year":"2005","unstructured":"Niemel\u00e4 H, Elima K, Henttinen T, Irjala H, Salmi M, Jalkanen S. Molecular identification of PAL-E, a widely used endothelial-cell marker. Blood. 2005;106(10):3405\u20139.","journal-title":"Blood"},{"issue":"3","key":"2133_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1076\/ceyr.22.3.190.5519","volume":"22","author":"AN Witmer","year":"2001","unstructured":"Witmer AN, van den Born J, Vrensen GFJM, Schlingemann RO. Vascular localization of heparan sulfate proteoglycans in retinas of patients with diabetes mellitus and in VEGF-induced retinopathy using domain-specific antibodies. Curr Eye Res. 2001;22(3):190\u20137.","journal-title":"Curr Eye Res"},{"issue":"7","key":"2133_CR55","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/ndt\/gfn758","volume":"24","author":"S Goldberg","year":"2009","unstructured":"Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH. Glomerular filtration is normal in the absence of both agrin and perlecan\u2013heparan sulfate from the glomerular basement membrane. Nephrol Dial Transplant. 2009;24(7):2044\u201351.","journal-title":"Nephrol Dial Transplant"},{"key":"2133_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/481520","author":"A Tojo","year":"2012","unstructured":"Tojo A, Kinugasa S. Mechanisms of glomerular albumin filtration and tubular reabsorption. Int J Nephrol. 2012;2012:481520. doi: 10.1155\/2012\/481520.","journal-title":"Int J Nephrol"},{"issue":"1","key":"2133_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ki.2013.490","volume":"86","author":"SS Roscioni","year":"2014","unstructured":"Roscioni SS, Heerspink HJL, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int. 2014;86(1):40\u20139.","journal-title":"Kidney Int"},{"issue":"2019","key":"2133_CR58","first-page":"2919080","volume":"21","author":"F Touzani","year":"2019","unstructured":"Touzani F, Geers C, Pozdzik A. Intravitreal injection of Anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;21(2019):2919080.","journal-title":"Case Rep Nephrol"},{"issue":"1","key":"2133_CR59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ckj\/sfy060","volume":"12","author":"RM Hanna","year":"2018","unstructured":"Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2018;12(1):92\u2013100.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2133_CR60","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2337\/db11-1024","volume":"61","author":"N Gil","year":"2012","unstructured":"Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 2012;61(1):208\u201316.","journal-title":"Diabetes"},{"issue":"5","key":"2133_CR61","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1046\/j.1523-1747.2001.15401.x","volume":"117","author":"D Bernard","year":"2001","unstructured":"Bernard D, M\u00e9hul B, Delattre C, Simonetti L, Thomas-Collignon A, Schmidt R. Purification and characterization of the endoglycosidase heparanase 1 from human plantar stratum corneum: a key enzyme in epidermal physiology? J Invest Dermatol. 2001;117(5):1266\u201373.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2133_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1095\/biolreprod.107.061317","volume":"77","author":"SS D\u2019Souza","year":"2007","unstructured":"D\u2019Souza SS, Daikoku T, Farach-Carson MC, Carson DD. Heparanase expression and function during early pregnancy in mice. Biol Reprod. 2007;77(3):433\u201341.","journal-title":"Biol Reprod"},{"key":"2133_CR63","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2019.01.017","volume":"283","author":"J Shu","year":"2019","unstructured":"Shu J, Santulli G. Heparanase in health and disease: the neglected housekeeper of the cell? Atherosclerosis. 2019;283:124\u20136.","journal-title":"Atherosclerosis"},{"issue":"6","key":"2133_CR64","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/fmc-2016-0012","volume":"8","author":"S Rivara","year":"2016","unstructured":"Rivara S, Milazzo FM, Giannini G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem. 2016;8(6):647\u201380.","journal-title":"Future Med Chem"},{"issue":"1","key":"2133_CR65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40425-018-0363-5","volume":"6","author":"E Hammond","year":"2018","unstructured":"Hammond E, Haynes NM, Cullinane C, Brennan TV, Bampton D, Handley P, et al. Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. J Immunother Cancer. 2018;6(1):54.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2133_CR66","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/anie.201410251","volume":"54","author":"PC Tyler","year":"2015","unstructured":"Tyler PC, Guimond SE, Turnbull JE, Zubkova OV. Single-entity heparan sulfate glycomimetic clusters for therapeutic applications. Angew Chem Int Ed. 2015;54(9):2718\u201323.","journal-title":"Angew Chem Int Ed"},{"issue":"8","key":"2133_CR67","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1021\/jm201708h","volume":"55","author":"V Ferro","year":"2012","unstructured":"Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, et al. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem. 2012;55(8):3804\u201313.","journal-title":"J Med Chem"},{"issue":"12","key":"2133_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/asia.202200228","volume":"17","author":"S Spijkers-Shaw","year":"2022","unstructured":"Spijkers-Shaw S, Campbell K, Shields NJ, Miller JH, Rendle PM, Jiao W, et al. Synthesis of novel glycolipid mimetics of heparan sulfate and their application in colorectal cancer treatment in a mouse model. Chem Asian J. 2022;17(12): e202200228.","journal-title":"Chem Asian J."},{"issue":"1","key":"2133_CR69","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12974-023-02925-4","volume":"20","author":"T Peck","year":"2023","unstructured":"Peck T, Davis C, Lenihan-Geels G, Griffiths M, Spijkers-Shaw S, Zubkova OV, et al. The novel HS-mimetic, Tet-29, regulates immune cell trafficking across barriers of the CNS during inflammation. J Neuroinflammation. 2023;20(1):251.","journal-title":"J Neuroinflammation"},{"issue":"155","key":"2133_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213671","volume":"1","author":"RAA Smith","year":"2023","unstructured":"Smith RAA, Luo X, Lu X, Tan TC, Le BQ, Zubkova OV, et al. Enhancing BMP-2-mediated osteogenesis with a synthetic heparan sulfate mimetic. Biomater Adv. 2023;1(155): 213671.","journal-title":"Biomater Adv"}],"updated-by":[{"DOI":"10.1186\/s12933-024-02170-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02133-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T10:37:50Z","timestamp":1708425470000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02133-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"12 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12933-024-02170-w","URL":"https:\/\/doi.org\/10.1186\/s12933-024-02170-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animals were kept according to the\u00a0<i>Guidelines on the Use of Animals in Research<\/i> and studies performed in compliance with the University of Bristol\u2019s guidelines and the Animal (Scientific Procedure) Act 1986 under licences approved by UK Home Office.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}